Markets

Genmab Presents Updated Phase 2 Data For Petosemtamab Plus Pembrolizumab In First-Line PD-L1–Positive Recurrent/Metastatic Head And Neck Cancer, At ESMO Congress 2026

Oct 26, 2026 · 07:18 AM ET· updated 58m ago

Median overall survival (OS) outcomes and encouraging anti-tumor activity observed with petosemtamab plus pembrolizumab in first-line (1L) recurrent or metastatic PD-L1+ head and neck squamous cell carcinoma (r/m

Why It Matters

Genmab's cancer medicine showed good results in a patient study. When companies share positive medicine news, it can signal progress toward helping patients and future sales.

This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.

Tickers in Play

GMAB44.45

+0.66 (+1.51%)

Last session drawn · prints held ~15 minutes · licensed exchange data

Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.

Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.